Hypoglycemia and cardiac arrhythmia in patients with diabetes mellitus type 2;Hypoglykämie und herzrhythmusstörungen bei patienten mit diabetes typ 2

Herz

Volumn 39, Issue 3, 2014, Pages 312-319

  Hanefeld, M ^a   Ganz, X ^a   Nolte, C ^b  

^a DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^b Praxis für Innere Medizin and Kardiologie Epidaurus   (Germany)

Author keywords

Arrhythmias; Cardiovascular complications; Frailty syndrome; Hypoglycemia; Hypoglycemic agents

Indexed keywords

ACARBOSE; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLUCAGON LIKE PEPTIDE 1; HEMOGLOBIN A1C; INSULIN; METFORMIN; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; SULFONYLUREA; ANTIARRHYTHMIC AGENT; ANTIDIABETIC AGENT;

AGED; ANGINA PECTORIS; ARTICLE; AUTONOMIC NEUROPATHY; BLOOD GLUCOSE MONITORING; CARDIOVASCULAR MORTALITY; CEREBROVASCULAR ACCIDENT; COMORBIDITY; DISEASE ASSOCIATION; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; HEART ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART INFARCTION; HEART VENTRICLE FIBRILLATION; HEART VENTRICLE TACHYCARDIA; HIGH RISK PATIENT; HUMAN; HYPOGLYCEMIA; ISCHEMIA; NON INSULIN DEPENDENT DIABETES MELLITUS; QT INTERVAL; RISK; SUDDEN DEATH; ARRHYTHMIAS, CARDIAC; CHEMICALLY INDUCED; COMPLICATION; DIABETES MELLITUS, TYPE 2; RISK ASSESSMENT; TREATMENT OUTCOME;

ANTI-ARRHYTHMIA AGENTS; ARRHYTHMIAS, CARDIAC; DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; RISK ASSESSMENT; TREATMENT OUTCOME;

EID: 84901357044     PISSN: 03409937     EISSN: 16156692     Source Type: Journal    
DOI: 10.1007/s00059-014-4086-1     Document Type: Article

References (61)

1. Tsujimoto T, Yamamoto-Honda R, Kajio H et al (2014) Vital signs, QT prolongation, and newly diagnosed cardiovascular disease during severe hypoglycemia in Type 1 and Type 2 diabetic patients. Diabetes Care 37:217-225
2. Desouza CV, Bolli GB, Fonseca V (2010) Hypoglycemia, diabetes, and cardiovascular events. Diabetes Care 33:1389-1394
3. Graveling AJ, Frier BM (2009) Hypoglycaemia: an overview. Prim Care Diabetes 3:131-139
4. American Diabetes Association (2013) Standards of medical care in diabetes - 2013. Diabetes Care 36(Suppl 1):S11-S66
5. Kosiborod M, Inzucchi SE, Goyal A et al (2009) Relationship between spontaneous and iatrogenic hypoglycemia and mortality in patients hospitalized with acute myocardial infarction. JAMA 301:1556-1564
6. McCoy RG, Van Houten HK, Ziegenfuss JY et al (2012) Increased mortality of patients with diabetes reporting severe hypoglycemia. Diabetes Care 35:1897-1901
7. ORIGIN Trial Investigators, Mellbin LG, Rydén L et al (2013) Does hypoglycaemia increase the risk of cardiovascular events? A report from the ORIGIN trial. Eur Heart J 34:3137-3144
8. Zoungas S, Patel A, Chalmers J et al (2010) Severe hypoglycemia and risks of vascular events and death. N Engl J Med 363:1410-1418
9. ACCORD Study Group, Gerstein HC, Miller ME et al (2011) Long-term effects of intensive glucose lowering on cardiovascular outcomes. N Engl J Med 364:818-828
10. Duckworth W, Abraira C, Moritz T et al (2009) Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 360:129-139
11. Tanenberg RJ, Newton CA, Drake AJ (2010) Confirmation of hypoglycemia in the "dead-in-bed" syndrome, as captured by a retrospective continuous glucose monitoring system. Endocr Pract 16:244-248
12. Heller SR (2002) Abnormalities of the electrocardiogram during hypoglycaemia: the cause of the dead in bed syndrome? Int J Clin Pract Suppl 129:27-32
13. Desouza C, Salazar H, Cheong B et al (2003) Association of hypoglycemia and cardiac ischemia: a study based on continuous monitoring. Diabetes Care 26:1485-1489 (Pubitemid 36929183)
14. Stahn A, Pistrosch F, Ganz X et al (2014) Relationship between hypoglycemic episodes and ventricular arrhythmias in patients with type 2 diabetes and cardiovascular diseases: silent hypoglycemias and silent arrhythmias. Diabetes Care 37:516-520
15. Frier BM, Schernthaner G, Heller SR (2011) Hypoglycemia and cardiovascular risks. Diabetes Care 34(Suppl 2):S132-S137
16. Amiel SA, Dixon T, Mann R, Jameson K (2008) Hypoglycaemia in Type 2 diabetes. Diabet Med 25:245-254 (Pubitemid 351322690)
17. Fisher BM, Gillen G, Dargie HJ et al (1987) The effects of insulin-induced hypoglycaemia on cardiovascular function in normal man: studies using radionuclide ventriculography. Diabetologia 30:841-845 (Pubitemid 18003664)
18. Marques JL, George E, Peacey SR et al (1997) Altered ventricular repolarization during hypoglycemia in patients with diabetes. Diabet Med 14:648-654 (Pubitemid 27346853)
19. Adler GK, Bonyhay I, Failing H et al (2009) Antecedent hypoglycemia impairs autonomic cardiovascular function: implications for rigorous glycemic control. Diabetes 58:360-366
20. Desouza CV, Bolli GB, Fonseca V (2010) Hypoglycemia, diabetes, and cardiovascular events. Diabetes Care 33:1389-1394
21. Ceriello A (1993) Coagulation activation in diabetes mellitus: the role of hyperglycaemia and therapeutic prospects. Diabetologia 36:1119-1125
22. Ceriello A (1997) Acute hyperglycaemia and oxidative stress generation. Diabet Med 14(Suppl 3):S45-S49
23. Huxley RR, Alonso A, Lopez FL et al (2012) Type 2 diabetes, glucose homeostasis and incident atrial fibrillation: the Atherosclerosis Risk in Communities study. Heart 98:133-138
24. Panova EI, Kruglova NE (2008) Factors associated with cardiac arrhythmias in patients with type 2 diabetes mellitus and myocardial infarction. Klin Med (Mosk) 86:23-26
25. Pochinka I, Strongin L, Struchkova J (2012) Glycaemic variability and ventricular cardiac arrhythmias in type 2 diabetic patients with chronic heart failure. 48th EASD Annual Meeting of the European Association for the Study of Diabetes, Abstr 230. Diabetologia 55(Suppl 1):S102
26. Lazar HL, McDonnell MM, Chipkin S et al (2011) Effects of aggressive versus moderate glycemic control on clinical outcomes in diabetic coronary artery bypass graft patients. Ann Surg 254:458-463
27. Monnier L, Colette C, Owens DR (2008) Glycemic variability: the third component of the dysglycemia in diabetes. Is it important? How to measure it? J Diabetes Sci Technol 2:1094-1100
28. Gerritsen J, Dekker JM, TenVoorde BJ et al (2001) Impaired autonomic function is ssociated with increased mortality, especially in subjects with diabetes, hypertension, or a history of cardiovascular disease: the Hoorn Study. Diabetes Care 24:1793-1798 (Pubitemid 33716484)
29. Heller SR (2008) Hypoglycemia in Type 2 diabetes. Diabetes Res Clin Pract 82(Suppl 2):S108-S111
30. Wright RJ, Frier BM (2008) Vascular disease and diabetes: is hypoglycaemia an aggravating factor? Diabetes Metab Res Rev 24:353-363
31. Clarke BF, Ewing DJ, Campbell IW (1979) Diabetic autonomic neuropathy. Diabetologia 17:195-212 (Pubitemid 10189639)
32. Psallas M, Tentolouris N, Cokkinos A et al (2006) QT dispersion: comparison between diabetic and non-diabetic individuals and correlation with cardiac autonomic neuropathy. Hellenic J Cardio 47:255-262 (Pubitemid 47621128)
33. Landstedt-Hallin L, Englund A, Adamson U, Lins PE (1999) Increased QT dispersion during hypoglycaemia in patients with type 2 diabetes mellitus. J Intern Med 246:299-307 (Pubitemid 29426449)
34. Inzucchi SE, Bergenstal RM, Buse JB et al (2012) Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 55:1577-1596
35. o A (2013) Executive summary: standards of medical care in diabetes - 2013. Diabetes Care 36(Suppl 1):S4-S10
36. Lachin JM, Orchard TJ, Nathan DM; DCCT/EDIC Research Group (2014) Update on cardiovascular outcomes at 30 years of the diabetes control and complications trial/epidemiology of diabetes interventions and complications study. Diabetes Care 37:39-43
37. White WB, Cannon CP, Heller SR et al (2013) Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med 369:1327-1335
38. Dormandy JA, Charbonnel B, Eckland DJ; PROactive investigators (2005) Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 366:1279-1289 (Pubitemid 41416583)
39. ORIGIN Trial Investigators, Mellbin LG, Rydén L et al (2013) Does hypoglycaemia increase the risk of cardiovascular events? A report from the ORIGIN trial. Eur Heart J 34:3137-3144
40. Scirica BM, Bhatt DL, Braunwald E; SAVOR-TIMI 53 Steering Committee and Investigators (2013) Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 369:1317-1326
41. UK Prospective Diabetes Study (UKPDS) Group (1998) Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 352:854-865
42. UK Prospective Diabetes Study (UKPDS) Group (1998) Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352:837-853
43. Chalmers J, Cooper ME (2008) UKPDS and the legacy effect. N Engl J Med 359:1618-1620
44. Nauck MA (2009) Unraveling the science of incretin biology. Eur J Intern Med 20(Suppl 2):S303-S308
45. Meier JJ, Schmidt WE, Klein HH (2007) New concepts in the treatment of type 2 diabetes. Internist (Berl) 48:698, 700-707
46. Garratt KN, Brady PA, Hassinger NL et al (1999) Sulfonylurea drugs increase early mortality in patients with diabetes mellitus after direct angioplasty for acute myocardial infarction. J Am Coll Cardiol 33:119-124 (Pubitemid 29064081)
47. Soydan N, Bretzel RG, Fischer B et al (2013) Reduced capacity of heart rate regulation in response to mild hypoglycemia induced by glibenclamide and physical exercise in type 2 diabetes. Metabolism 62:717-724
48. Lopez-Liuchi JV, Meier CA (1999) Therapy for type 2 diabetes: where do we stand after the UK prospective diabetes study? Eur J Endocrinol 140:4-6 (Pubitemid 29074759)
49. Juurlink DN, Gomes T, Shah BR, Mamdani MM (2012) Adverse cardiovascular events during treatment with glyburide (glibenclamide) or gliclazide in a high-risk population. Diabet Med 29:1524-1528
50. Mellbin LG, Malmberg K, Norhammar A et al (2011) Prognostic implications of glucose-lowering treatment in patients with acute myocardial infarction and diabetes: experiences from an extended follow-up of the Diabetes Mellitus Insulin-Glucose Infusion in Acute Myocardial Infarction (DIGAMI) 2 Study. Diabetologia 54:1308-1317
51. Matsumoto T, Lopes RA, Taguchi K et al (2014) Linking the beneficial effects of current therapeutic approaches in diabetes to the vascular endothelin system. Life Sci [Epub ahead of print]
52. Monnier L, Colette C, Michel F et al (2011) Insulin therapy has a complex relationship with measure of oxidative stress in type 2 diabetes: a case for further study. Diabetes Metab Res Rev 27:348-353
53. Scognamiglio R, Negut C, Kreutzenberg SV de et al (2006) Effects of different insulin regimes on postprandial myocardial perfusion defects in type 2 diabetic patients. Diabetes Care 29:95-100 (Pubitemid 44033438)
54. Engler B, Koehler C, Hoffmann C et al (2011) Relationship between HbA1c on target, risk of silent hypoglycemia and glycemic variability in patients with type 2 diabetes mellitus. Exp Clin Endocrinol Diabetes 119:59-61
55. Hanefeld M, Koehler C, Hoffmann C et al (2010) Effect of targeting normal fasting glucose levels with basal insulin glargine on glycaemic variability and risk of hypoglycaemia: a randomized, controlled study in patients with early Type 2 diabetes. Diabet Med 27:175-180
56. Fonseca V, Gill J, Zhou R, Leahy J (2011) An analysis of early insulin glargine added to metformin with or without sulfonylurea: impact on glycaemic control and hypoglycaemia. Diabetes Obes Metab 13:814-822
57. Holman RR, Farmer AJ, Davies MJ et al (2009) Three-year efficacy of complex insulin regimens in type 2 diabetes. N Engl J Med 361:1736-1747
58. Riddle MC, Rosenstock J, Gerich J; Insulin Glargine 4002 Study Investigators (2003) The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care 26:3080-3086 (Pubitemid 37339502)
59. Laubner K, Molz K, Kerner W et al (2013) Daily insulin doses and injection frequencies of Neutral Protamine Hagedorn (NPH) insulin, insulin detemir and glargine in type 1 and type 2 diabetes: a multicenter analysis of 51 964 patients from the German/Austrian DPV-Wiss database. Diabetes Metab Res Rev [Epub ahead of print]
60. Bretzel RG, Nuber U, Landgraf W et al (2008) Once- daily basal insulin glargine versus thrice-daily prandial insulin lispro in people with type 2 diabetes on oral hypoglycaemic agents (APOLLO): an open randomised controlled trial. Lancet 371:1073-1084 (Pubitemid 351436611)
61. Janka HU, Plewe G, Riddle MC et al (2005) Comparison of basal insulin added to oral agents versus twice-daily premixed insulin as initial insulin therapy for type 2 diabetes. Diabetes Care 28:254-259 (Pubitemid 40170922)